Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II safety of intravitreal mesenchymal stem cells for acute NAION
2016-003029-40Phase 2Active
- Sponsor
- Universidad de Valladolid
- Start
- Dec 2016
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of allogeneic bone marrow-derived mesenchymal stromal cells in non-arteritic anterior ischemic optic neuropathy (NAION), sponsored by Universidad de Valladolid. Primary endpoint: Composite main safety endpoint. Started Dec 2016; status: active.
02
Drugs
allogeneic bone marrow-derived mesenchymal stromal cells
03
Conditions
non-arteritic anterior ischemic optic neuropathy (NAION)
Beyond the preview
Go deeper on 2016-003029-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003029-40.